Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(50.0%)
Phase 1
1(25.0%)
Phase 2
1(25.0%)
4Total
Phase 4(2)
Phase 1(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT07313358Not Yet Recruiting

10119473 -VIROMARKERS HDV Biomarkers Study

Role: collaborator

NCT06472362Enrolling By Invitation

Chest CT Biomarkers as Prognostic Predictors in SSc-ILD

Role: collaborator

NCT07065825Not Yet Recruiting

Tumor Rupture During Robotic Partial Nephrectomy

Role: collaborator

NCT01521611Phase 1Completed

Targeted Radiotherapy in HSCT for Poor Risk Haematological Malignancy

Role: collaborator

NCT00442975Phase 4Completed

Response of Older Adults to Influenza Vaccination With Regard to Cytomegalovirus (CMV) Status

Role: collaborator

NCT00405236Phase 4Completed

Effect of Tiotropium on Inflammation and Exacerbations in COPD

Role: lead

NCT00147667Phase 2Unknown

Effects of Long Term Macrolide Antibiotic Therapy in Patients With COPD

Role: lead

All 7 trials loaded